Global Epigenetics Market 2017-2021
Epigenetics is a biological process to control gene expression by altering the chromatin structure. Genes which are going to be expressed are associated with accessible chromatin regions, whereas silent genes are often associated with inaccessible chromatin regions. Epigenetics products that include reagents, kits, enzymes, instruments, and drugs help in analyzing epigenetic changes on the basis of which epigenetic therapy develops.
Technavio’s analysts forecast the global epigenetics market to grow at a CAGR of 13.22% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global epigenetics market for 2017-2021. To calculate the market size, the report considers the revenue generated from the retail sales of epigenetics products.The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Epigenetics Market 2017-2021
Technavio recognizes the following companies as the key players in the global epigenetics market: Abcam, Bio-Rad Laboratories, Merck, and Thermo Fisher Scientific.
Other Prominent Vendors in the market are: Active Motif, BellBrook Labs, BioVision, CELGENE, Cisbio.com, Diagenode, Epizyme, Illumina, New England Biolabs, Novartis, and QIAGEN.
Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is increasing demand for personalized medicine. The demand for personalized medicine is increasing and is expected to grow in future with a CAGR of more than 10%. The development of whole genome technology, companion diagnostics, and the growing number of retail clinics are some reasons for its growth.”
According to the report, one driver in the market is increasing prevalence of cancer. Epigenetic mechanisms are essential for the normal development and maintenance of tissue-specific gene expression patterns in mammals. The disruption of epigenetic processes can lead to the malicious transformation of cells and altered gene function. Alteration in the heritable epigenetic marks can result in inappropriate activation or inhibition of various signaling pathways and lead to disease states such as cancer. Cancer is one of the major public health problems globally. It is one of the leading causes of death. It was estimated that in 2012, more than 2% new cancer cases occurred globally.
Further, the report states that one challenge in the market is difficulty in finding predictive epigenetic biomarker. A biomarker is a characteristic that is accurately measured and evaluated as an indicator of normal biological processes, pharmacologic responses, or pathogenic processes to a therapeutic intervention. It is any structure, substance, or method that can be measured in the body. It can be a product such as protein after gene expression, which can predict the incidence or outcome of a disease. The use of biomarkers in clinical and basic research as well as in clinical practice has become so ordinary that their presence as primary endpoints in clinical trials is now accepted almost without question.
Abcam, Bio-Rad Laboratories, Merck, Thermo Fisher Scientific, Active Motif, BellBrook Labs, BioVision, CELGENE, Cisbio.com, Diagenode, Epizyme, Illumina, New England Biolabs, Novartis, and QIAGEN.